Možnosti léčby myelodysplastického syndromu v roce 2021
[Treatment strategies for myelodysplastic syndrome in 2021]
Jazyk čeština Země Česko Médium print
Typ dokumentu časopisecké články
PubMed
34171954
PII: 127306
- Klíčová slova
- azacitidin, erythropoiesis-stimulating agents, lenalidomid, lenalidomide, myelodysplastic syndromes, treatment, type 2 diabetes,
- MeSH
- lidé MeSH
- myelodysplastické syndromy * MeSH
- prognóza MeSH
- progrese nemoci MeSH
- riziko MeSH
- transplantace hematopoetických kmenových buněk * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
The heterogeneous nature of myelodysplastic syndrome (MDS) brings a very variable prognosis of patients with the need for individualized treatment. The prognosis and treatment depend on the conventional determination of IPSS (International Prognostic Scoring System) and its revised form IPSS-R, which divides patients into lower and higher risk groups. Treatment of patients with lower risk of MDS include the improvement of cytopenia, especially anemia. The goal of treatment in patients with higher risk of MDS is delaying disease progression and improve patient survival. The only curative method for therapy of MDS is allogeneic hematopoietic stem cell transplantation (HSCT), howewer it is rarely applicable due to the age and comorbidities of patients.